Antigenics Inc. is a biotechnology company engaged in the discovery and development of a family of novel drugs for the treatment of life-threatening and chronic medical conditions. The company's products are based on a specific class of proteins known as heat shock proteins (HSPs) and their ability to program the immune system. The company's products include cancer drugs in the newly emerging field of personalized medicine. In addition, Antigenics' product portfolio includes drugs for the treatment of infectious diseases, such as genital herpes, and autoimmune disorders, such as diabetes and multiple sclerosis, that do not require personalized therapies. The company is currently evaluating its lead immunotherapeutic, OncophageŽ, in an international multi-center Phase III clinical trial in renal cell carcinoma and has completed Phase II or I/II trials in several additional indications. Based upon Antigenics' scientific and drug development skills, its technology platform and strategic expertise, the company plans to establish a leadership position in drug discovery, development and commercialization.
- Research & Development
Product / Technology type(s) covered:
United States of America